Salute e Benessere

Bavarian Nordic Awarded USD 63 Million from the U.S. Government for Production…

Contract will further strengthen the U.S, bulk vaccine inventory and secure additional freeze-dried dosesDeliveries planned for 2025 and beyondCOPENHAGEN, Denmark, September 24, 2024– Bavarian Nordic A/S (OMX: BAVA) today announced that it has received an additional order valued at USD 63 million from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and...
Nasdaq GlobeNewswire
24/09/2024

LET IT RAIN DIAMONDS: DAR GLOBAL AND MOUAWAD HIGH JEWELLERY HOUSE UNVEIL SAR 880…

Set for handover in Q4 of 2026, the luxury development of 200 residential villas will become one ofRiyadh'smost prestigious addresses, bringing together the expertise of Dar Global, known for its innovative approach to high-end real estate, and Mouawad's legacy of creative and artistic mastery. Owners of residential properties worth 4 million Saudi Riyals and above are granted eligibility to Real Estate Owner Residency under the Saudi Premium Residency program. The program,...
PR Newswire
24/09/2024

Levothyroxine Sodium API Market Size to Grow USD 42 Million by 2030 at a CAGR of…

Get Free Sample: https://reports.valuates.com/request/sample/QYRE-Auto-14Z13268/Global_Levothyroxine_Sodium_API_Market Get Free Sample: https://reports.valuates.com/request/sample/QYRE-Auto-14Z13268/Global_Levothyroxine_Sodium_API_Market Major Trends : The Levothyroxine Sodium API market is growing steadily, driven by the rising prevalence of thyroid disorders, particularly hypothyroidism. Increasing diagnosis rates and the expanding geriatric population, which is more susceptible...
PR Newswire
24/09/2024

Beta Glucan Market Surges to USD 31 Billion by 2030, Propelled by 3.24% CAGR -…

Download PDF Brochure: https://www.verifiedmarketreports.com/download-sample/?rid=498953 Download PDF Brochure: https://www.verifiedmarketreports.com/download-sample/?rid=498953 Browse in-depth TOC on Beta Glucan Market 202 – Pages 126 – Tables 37 – Figures Scope of The Report Global Beta Glucan Market Overview Market Drivers Fueling Growth in the Beta Glucan Market Increasing Health Awareness The growing focus on health and wellness among consumers...
PR Newswire
24/09/2024

BIOVAXYS ANNOUNCES CLOSING OF FOURTH TRANCHE OF PRIVATE PLACEMENT

The Company intends to use the proceeds of the Private Placement for general working capital purposes, including enabling the Company to fund and advance its business plans in regard to its successful recent acquisition of the entire portfolio of discovery, preclinical and clinical development stage assets in oncology, infectious disease, antigen desensitization, and other immunological fields based on the DPX™ immune educating platform technology, developed by the former Canadian biotechnology…
PR Newswire
24/09/2024

Curium Announces the Official Opening its New Netherlands Facility for the…

The new Lu-177 production facility further solidifies Curium's position as a global leader in nuclear medicineCurium will ensure a continuous supply of Lu-177 to benefit more than 100,000 cancer patients worldwide over the next 5 yearsLu-177 is a 'game changer' therapy isotope for the treatment of cancer patientsPARIS, Sept.24, 2024(GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that it has officially opened an additional and new facility in Petten,...
Nasdaq GlobeNewswire
24/09/2024

inThought and inThought Labs Announce AI Initiative: Cut Down Tedious Tasks

Along with the ever-increasing amounts of data and opinion at our fingertips, decision makers in all industries struggle to find the right information and the best insights. inThought Labs, the technology division of inThought, collaborates with drug makers to develop both human intelligence and artificial intelligence solutions, with the goal of elevating daily tasks from tedious information sorting to insight generation and decision making. Along with the ever-increasing amounts of data and...
PR Newswire
24/09/2024

Kennametal Expands Mining Portfolio with Three New Product Lines

PrimePoint™ features a polycrystalline diamond (PCD) tip, enabling longwall operators to mine longer. With increased hardness over traditional tungsten carbide, abrasive wear to the PCD tip is significantly reduced, increasing uptime. PrimePoint™ features a polycrystalline diamond (PCD) tip, enabling longwall operators to mine longer. With increased hardness over traditional tungsten carbide, abrasive wear to the PCD tip is significantly reduced, increasing uptime. Developed to meet a...
PR Newswire
24/09/2024

AI4HealthyCities: Novartis Foundation reveals potential associations between…

Detailed Research FindingsWhile the data does not imply any correlations between one or multiple SDOH and cardiovascular health outcomes, AI4HealthyCities uncovered several distinct patterns across New York City: Detailed Research FindingsWhile the data does not imply any correlations between one or multiple SDOH and cardiovascular health outcomes, AI4HealthyCities uncovered several distinct patterns acrossNew York City : Dr.Ann Aerts, Head of the Novartis Foundation, emphasized the...
PR Newswire
24/09/2024

Cepheid Partners with Fleming Initiative to Fight Antimicrobial Resistance (AMR)

The Fleming Initiative and Cepheid will introduce the partnership at an event in New York aligned with the United Nations General Assembly High Level Meeting about AMR1. The Fleming Initiative and Cepheid will introduce the partnership at an event inNew Yorkaligned with the United Nations General Assembly High Level Meeting about AMR 1. The Fleming Initiative brings together research scientists, policymakers, clinicians, behavioral experts, public and commercial partners to provide the...
PR Newswire
24/09/2024

Veltassa® (patiromer) approved in Japan for the treatment of adults with…

ST. GALLEN, Switzerland, Sept. 24, 2024 /PRNewswire/ -- CSL Vifor today announced that Japan's Ministry of Health and Labor Welfare (MHLW) has granted its partner, Zeria Pharmaceutical Co., Ltd. (Zeria), marketing authorization approval for Veltassa® for the treatment of adult patients with hyperkalemia, a condition characterized by high levels of potassium in the blood. Veltassa® has now received marketing authorizations in 41 countries worldwide. ST. GALLEN,Switzerland,Sept. 24, 2024...
PR Newswire
24/09/2024

Groupe Casino: Changes in governance at Monoprix and Naturalia

Changes in governance at Monoprix and Naturalia Philippe PALAZZI, Chief Executive Officer of Casino Group, appointed Chairman of Monoprix and Chairman of Naturalia on top of his current role Alfred HAWAWINI, Group Transformation and Strategy Director, named Chief Executive Officer at Monoprix Changes have been made to the Group's governance with a view to furthering the implementation of its transformation plan. Accordingly, Philippe PALAZZI will now chair Monoprix and...
Nasdaq GlobeNewswire
24/09/2024

Invitation to presentation of Essity's interim report for quarter 3, 2024

Contact information for conference call with the possibility to ask questions:UK: +44 (0) 33 0551 02 00 USA: +1 786 697 35 01SWE: +46 (0)8 505 204 24Please call in well in advance of the start of the presentation. Indicate: "Essity". Contact information for conference call with the possibility to ask questions: UK: +44 (0) 33 0551 02 00 USA : +1 786 697 35 01 SWE: +46 (0)8 505 204 24 Please call in well in advance of the start of the presentation. Indicate…
PR Newswire
24/09/2024

SCIENCE AND PLANNING LEADERS CALL ON UK GOVERNMENT FOR NEW MODEL OF…

The Infrastructure & Project Authority's Project Director in the Housing and Delivery Team Karl FitzGerald commented: 'I am taken by the concept of mission-based government – a collaborative approach - it's the only way we can crack things. It can be done but it will take a culture change at the top.' The Infrastructure & Project Authority's Project Director in the Housing and Delivery Team Karl FitzGerald commented: 'I am taken by the concept of mission-based government – a…
PR Newswire
24/09/2024

Basilea initiates clinical phase 3 study with antifungal fosmanogepix in…

Allschwil, Switzerland, September 24, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it has initiated the Fosmanogepix Against Standard-of-care Treatment in Invasive Candidiasis (FAST-IC) phase 3 study. This registrational study evaluates the efficacy and safety of Basilea's broad-spectrum antifungal fosmanogepix in the treatment of...
Nasdaq GlobeNewswire
24/09/2024

Roche launches the first test to use its breakthrough TAGS technology for high…

New TAGS (Temperature-Activated Generation of Signal) technology enables up to 15 targets to be detected simultaneously in a single patient sample on the high throughput molecular diagnostic analysers cobas 5800, 6800 and 8800.TAGS has the potential to revolutionise testing for other infectious diseases in the future, by bringing high throughput customised syndromic panel testing to the routine clinical laboratory.The first TAGS-based test to be made available, the cobas Respiratory...
Nasdaq GlobeNewswire
24/09/2024

Santhera Announces Acceptance by Swissmedic of Marketing Authorization…

Pratteln, Switzerland, September 24, 2024 – Santhera Pharmaceuticals (SIX: SANN) announces that Swissmedic, the Swiss Agency for Therapeutic Products, has accepted for review the marketing authorization application (MAA) for AGAMREE® (vamorolone) for the treatment of Duchenne muscular dystrophy (DMD). Santhera asked Swissmedic to assess AGAMREE® as part of Article 13 TPA (therapeutics product act) procedure, allowing it to consider the results of foreign regulatory authorities' assessments...
Nasdaq GlobeNewswire
24/09/2024

UCB and Biogen Announce Positive Topline Results From Phase 3 Study of…

Phase 3 PHOENYCS GO study met the primary endpoint demonstrating clinical improvement in moderate-to-severe systemic lupus erythematosus; Clinical improvements were observed among key secondary endpoints measuring disease activity and flares.UCB and Biogen are advancing dapirolizumab pegol with the objective to address the substantial unmet medical need for people living with SLE, where there are limited treatment options.SLE is a chronic, debilitating autoimmune disease that affects...
Nasdaq GlobeNewswire
24/09/2024

BRIAN COX WARNS THE WORLD ABOUT WORKPLACE MENTAL HEALTH THREAT IN PSA FOR ASICS

ASICS' global State of Mind study, involving 26,000 participants, revealed a strong connection between sedentary behaviour and mental wellbeing with State of Mind scores declining the longer individuals remain inactive1. Further research into desk-based working found that after just two hours of continuous desk work State of Mind scores begin to drop and stress levels rise2. After four hours of uninterrupted desk time, workers' stress levels increased significantly by 18%. However, a new Desk…
PR Newswire
24/09/2024

Non-Muscle Invasive Bladder Cancer Market Set to Reach New Heights Amidst…

Based on DelveInsight's assessment in 2023, the total prevalent cases of NMIBC in the 7MM were nearly 1.5 million. These cases are expected to increase by 2034. Among cases categorized by risk level, the highest number belonged to the intermediate-risk category. Based on DelveInsight's assessment in 2023, the total prevalent cases of NMIBC in the 7MM were nearly 1.5 million. These cases are expected to increase by 2034. Among cases categorized by risk level, the highest number belonged to...
PR Newswire
23/09/2024

DBV Technologies Completes Screening for the VITESSE Phase 3 Clinical Trial

DBV Technologies Completes Screening for the VITESSE Phase 3 Clinical Trial In Q3 2024, DBV exceeded its recruitment goal and successfully closed the screening process for the VITESSE Phase 3 study evaluating the Viaskin ®Peanut Patch in peanut allergic children ages 4 – 7 years oldTopline results of VITESSE data are expected by Q4 2025DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today...
Nasdaq GlobeNewswire
23/09/2024

Crossject reports financial results and business highlights for the first six…

Available cash €5.95 million, up from €2.3 million on December 31, 2023Reports stable investments in R&D and consolidation of operating income from BARDACompany on track to successfully file for the Emergency Use Authorization for its epilepsy rescue therapy in early 2025Dijon, France, September 23, 2024 18:00 CET --Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company developing the award-winning needle-free ZENEO® auto-injector to deliver...
Nasdaq GlobeNewswire
23/09/2024

Spineway : Half-year results 2024

SPINEWAYHalf-year results 2024Half-year turnover of €6.5 million (+20%)Improvement in operating incomeFull effect of savings measures visible in the 2nd half of 2024In thousands of EurosConsolidated accountsS1 2024S1 2023Turnover6 5355 432 Cost of sales- 2 059- 1 509 Gross margin% of turnover4 47668%3 92372% Net operating costs Of which operating costs - 5 246 - 2 232 - 5 556-2 355 Of...
Nasdaq GlobeNewswire
23/09/2024

SPINEWAY: Half-year financial statements 2024

SPINEWAYHalf-year financial statements 2024 Attachment Consolidated financial statements – 06 30 2024
Nasdaq GlobeNewswire
23/09/2024
Altri  Comunicati